Indium (111In) capromab pendetide
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | prostatic carcinoma cells |
| Clinical data | |
| Trade names | Prostascint |
| Identifiers | |
151763-64-3  (capromab)148805-91-8 (pendetide) | |
| V09IB04 | |
| ChEMBL |
CHEMBL1201579 |
| Chemical data | |
| (what is this?) (verify) | |
Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.[1] Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen (PSMA) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).[1]
Early trials with yttrium (90Y) capromab pendetide were also conducted.[3]
References
- ↑ 1.0 1.1 Manyak, M. J. (2008). "Indium-111 capromab pendetide in the management of recurrent prostate cancer". Expert Review of Anticancer Therapy 8 (2): 175–122. doi:10.1586/14737140.8.2.175. PMID 18279057.
- ↑ WHO Drug Information
- ↑ Kahn, Daniel; J. Christopher Austin; Robert T. Maguire; Sara J. Miller; Jack Gerstbrein; Richard D. Williams (1999). "A Phase II Study of [90Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy". Cancer Biotherapy & Radiopharmaceuticals 14 (2): 99. doi:10.1089/cbr.1999.14.99.
| ||||||||||||||||||||||||||||||||||||||||||